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RB, p107, and p130 are highly related proteins, each capable of regulating cellular proliferation. However,
only RB is frequentlymutated in cancer. In this issue ofCancer Cell, Chicas et al. shed new light on this conun-
drum, defining a ‘‘special,’’ nonredundant role for RB in promoting cellular senescence.Cellular senescence is a durable growth
arrest that occurs in response to a variety
of cellular insults including telomere dys-
function, DNA damage, oxidative stress,
and/or oncogene activation (Campisi
and d’Adda di Fagagna, 2007). In re-
sponse to these stressors, the archetypal
tumor-suppressor proteins p53 and
p16INK4a promote cell cycle arrest and
cellular senescence through inhibition of
cyclin-dependent kinase (CDK) activity.
In the absence of CDK phosphorylation,
the RB family of proteins (RB, p107, and
p130) binds E2F transcription factors
and blocks S-phase entry. Intriguingly,
although all three ‘‘pocket proteins’’
have the capability to block cellular prolif-
eration at the G1-S checkpoint, only RB
is mutated with high frequency in
human cancers (see COSMIC, http://
www.sanger.ac.uk/genetics/CGP/cosmic/).
This observation has prompted many
investigators to wonder what makes RB
so ‘‘special,’’ at least with regard to tumor
suppression.
One hypothesis, based upon the selec-
tive binding of RB, p107, and p130 to
specific E2F family members, has been
that the antioncogenic properties of RB
can be attributed to a unique set of tran-
scriptional targets. Several groups have
tested this model via candidate gene
approaches in knockout murine embryo
fibroblasts (MEFs) and cancer cell lines
(e.g., Hurford et al., 1997; Lehmann
et al., 2008). Although these studies sug-
gested that the pocket proteins control
specific subsets of E2F-regulated genes
(e.g., cyclin E), the consequences of
such selectivity were not fully understood.
Moreover, the use of tumor-derived or
germline knockout cell lines for these
analyses failed to account for functionalchanges in the cell cycle machinery re-
sulting from transformation or develop-
mental compensation.
Against this background, Chicas and
colleagues now provide additional
insights into the nonredundant functions
of RB family members through the use of
unbiased technologies (Chicas et al.,
2010). The authors evaluated cellular
quiescence, cellular senescence, and
gene expression after knockdown of
each pocket protein individually in non-
transformed human fibroblasts. They
further used chromatin immunoprecipita-
tion and unbiased next-generation
sequencing (ChIP-Seq) to identify DNA
sites bound specifically by each RB family
member in cycling, senescent, or quies-
cent cells.
Supporting the dogma that pocket
proteins control cell cycle progression
primarily through E2F regulation, a large
number of the differentially regulated
genes identified in their screen were
known E2F targets. In addition, knock-
down of RB, p107, or p130 individually
failed to abrogate quiescence induced
by contact inhibition or serum starvation.
Only upon targeting of all three genes at
once were cells able to bypass the G1-S
checkpoint in the setting of quiescence
(Figure 1). These data are in accord with
other recent publications (Reed et al.,
2010; Stengel et al., 2009), demonstrating
redundancy among the RB family mem-
bers during normal growth and quies-
cence. However, when the authors exam-
ined RB family protein binding in the
context of cellular senescence, they
observed a distinction between RB and
p107/p130.
To examine oncogene-induced senes-
cence, Chicas and colleagues transducedCancer Celfibroblasts with a retrovirus expressing
oncogenic RAS in the presence or
absence of shRNAs specific to each RB
family member. Knockdown of no single
RB family member was sufficient to fully
abrogate RAS-induced growth arrest.
Intriguingly, however, knockdown of RB,
but not p107 or p130, did substantially
overcome aspects of the senescence-
promoting effect of RAS expression, in-
creasing DNA replication and reducing
expression of senescence markers such
as senescence-associated (SA) hetero-
chromatin formation and SA-b-galactosi-
dase (Figure 1). Moreover, gene profiling
experiments combined with ChIP-Seq
data showed regulation of an interesting
subset of genes in the setting of senes-
cence by RB, but not p130 or p107. In
accord with other studies of RB function,
many of these senescence-associated,
RB-specific targets were DNA replication
factors or genes expressed as part
of the senescence-associated secretory
phenotype. The authors also observed a
novel cluster of RB-specific targets that
are largely uncharacterized in function.
The only familiar member of this cluster
was cyclin E1, a well-known RB target
that induces CDK2 activity and further
phosphorylation of RB family members
(Herrera et al., 1996).
Provocatively, cyclin E1 is also believed
to stimulate prereplication complex (pre-
RC) formation through the CDK-indepen-
dent recruitment of minichromosome
maintenance proteins (MCMs) to DNA
replication origins (Geng et al., 2007). On
the basis of the observation that cyclin
E1 was potently induced by RB loss in
the context of senescence, the authors
proposed a two-pronged mechanism by
which RB inhibits replication in the settingl 17, April 13, 2010 ª2010 Elsevier Inc. 313
Figure 1. RB Is Critical to Cellular Senescence
Top: Knockdown of RB, p107, or p130 in quiescent normal human fibroblasts fails to influence proliferation
or loading of the pre-RC complex onto replication origins. Only upon loss of all three proteins do cells begin
to traverse the G1-S checkpoint.
Bottom: Normal fibroblasts senesce upon the expression of an oncogenic RAS showing increased
SA-b-galactosidase expression (blue) and heterochromatin foci (blue circles). Knockdown of RB, but
not p107 or p130, allows the cells to partially escape senescence through induction of DNA replication
factors and cyclin E1. This process leads to pre-RC formation and limited endoreduplication (red) and
requires cyclin E1. Additional loss of p53 or p21CIP provides further resistance to senescence.
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Previewsof senescence: by repression of tran-
scripts associated with DNA replication
and by repression of cyclin E1, which
participates in pre-RC formation. As pre-
dicted by this model, concomitant knock-
down of cyclin E1 and RB in senescing
fibroblasts inhibited pre-RC formation
and reduced the aberrant DNA replication
observed with RB deficiency alone (Fig-
ure 1). In addition, the reintroduction of
shRNA-resistant wild-type and kinase-
deficient cyclin E1 cDNAs caused the
cells to revert to aberrant proliferation
and endoreduplication. Therefore, dereg-
ulation of cyclin E1 alone appears to be
responsible for the aberrant replication
seen in senescing cells lacking RB.
Cells lacking RB escaped from onco-
gene-induced senescence only tempo-
rarily. After additional passaging, these
cells arrested, suggesting the existence
of additional proliferative barriers. Based
upon previous work demonstrating the
cooperativity of loss of p53 and RB in
cellular transformation, the authors exam-
ined the role of p53 in the RB-deficient cell
lines. Remarkably, knockdown of p53
or its transcriptional target, the p21CIP
cyclin-dependent kinase inhibitor, al-314 Cancer Cell 17, April 13, 2010 ª2010 Elslowed RB-deficient cells to undergo sus-
tained proliferation, suggesting a critical
interaction between these pathways in
oncogene-induced senescence.
The finding that p107 and p130 fail to
compensate for RB loss in the setting of
oncogene-induced senescence raises
several new questions. The molecular
basis whereby p107 and p130 are able
to sufficiently repress transcription of
DNA replication factors and cyclin E1 in
the setting of generic G1 arrest (quies-
cence), but not during senescence, is
unknown. Moreover, it is unclear whether
these nonredundant RB functions can be
extended to other cell types. Recent pub-
lications have suggested tissue-specific
roles for the pocket proteins in murine
homeostasis. For example, although loss
of RB and p130 function failed to increase
hepatic proliferation (Reed et al., 2010),
mutation of these two proteins in the
intestinal epithelium led to hyperprolifera-
tion (Haigis et al., 2006). Moreover, the
pocket proteins have recently been re-
ported to regulate their own transcription
in a tissue-specific manner (Burkhart
et al., 2010). A tissue specificity in the
ability of p107 and/or p130 to provideevier Inc.compensation for RB loss may in turn
explain why RB inactivation is so strongly
associated with transformation of some
tissues (e.g., the retina), but not others.
As a whole, this work substantially
clarifies our understanding of RB family
function, identifying an unexpected,
nonredundant role for RB in senescence
but not quiescence. This function of RB
is mediated by increased promoter affinity
and gene regulation of several factors
involved in DNA replication, as well as
cyclin E1, which plays a newly discov-
ered, noncatalytic role in DNA replication.
Through these actions, RB appears
unique among RB family members in its
ability to fully and durably promote cellular
senescence, arguably the most important
of mammalian tumor-suppressor mecha-
nisms. In this regard, RB appears truly to
be special, proving that, at least when it
comes to tumor suppression, three
proteins are not better than one.REFERENCES
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